Minimally-invasive Gene Delivery Of A Novel Inhibitor Of Retinal Angiogenesis
Funder
National Health and Medical Research Council
Funding Amount
$883,883.00
Summary
Excessive growth of blood vessels in the eye causes vision loss and can only be treated with lasers or painful and frequent injections into the eye. Vasostatin is a specific inhibitor of angiogenesis and a promising agent for the management of ocular neovascularisation. We will provide pre-clinical evidence that gene delivery of vasostatin-like peptides is an effective therapeutic strategy and it has potential to revolutionize the current ophthalmic care of age-related macular degeneration.
The Role Of Estrogen Signalling In The Development And Progress Of Neovascularisation In Macular Degeneration
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
Age-related macular degeneration is a common eye disease. In the advanced stages of the disease, abnormal and leaky blood vessels form, causing permanent and severe vision loss. A novel treatment is the application of the sex hormone, estrogen, which could halt abnormal blood vessel growth in the eye. This project aims to confirm the protective effects of estrogen on eye health and whether mutations in estrogen-related genes alter the risk of vision loss due to abnormal blood vessel growth.
A Novel Treatment For Ameliorating Retinal Vascular Disease
Funder
National Health and Medical Research Council
Funding Amount
$366,685.00
Summary
Retinal vascular disease is a leading cause of blindness and is currently treated by laser photocoagulation surgery. Although successful, this treatment is associated with serious side effects. Recently, Ellex Pty has developed a novel laser called the 2RT laser that is likely to be effective without the accompanying side effects. This study will allow examine the effect of the 2RT laser in animal models of retinal vascular disease so as to complete preclinical development of this laser.
Glial-neuronal-vascular Interactions In A Novel Transgenic Model Of Muller Cell Dysfunction
Funder
National Health and Medical Research Council
Funding Amount
$626,585.00
Summary
Muller cell disfunction is a feature shared by many retinal diseases. This project aims to study the contribution of Muller cell dysfunction to retinal neuronal damage and blood-retinal barrier breakdown in a novel transgenic model we recently generated. Results of this study will also be of interest to scientists and clinicians seeking to understand better and treat diseases of the central nervous system in general.
Improving Inner Retinal Oxygenation: Developing A New Form Of Retinal Laser Photocoagulation Therapy
Funder
National Health and Medical Research Council
Funding Amount
$408,818.00
Summary
Diabetic retinopathy is the major cause of vision loss in the working age population in our community. Current therapy involves laser destruction of much of the peripheral retina to protect the central vision. However, recent clinical and experimental evidence suggests that more moderate laser therapy could be sufficient, and that useful vision in the laser treated area can be preserved. Benefits to the patient would include reduced loss of visual field, and reduced night blindness.